BLS Pharmaceuticals Limited (ASX:BLS)
Australia · Delayed Price · Currency is AUD 0.9000
-0.0200 (-2.17%)
Aug 11, 2026, 4:10 PM AEST
BLS Pharmaceuticals Financials Overview
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Revenue Revenue Growth | 47.95 | 29.28 | 9.64 | 5.3 | 0.46 | 2.2 |
Revenue Growth | 63.77% | 203.66% | 81.97% | 1042.88% | -78.97% | -5.61% |
Gross Profit Gross Profit Growth | 19.69 | 11.18 | 3.72 | 1.57 | 0.13 | 0.95 |
Operating Income Operating Income Growth | 9.91 | 5.1 | -1.13 | -1.82 | -0.45 | -0.37 |
Net Income Net Income Growth | 8.97 | 4.9 | -13.33 | -1.94 | -0.49 | -0.5 |
Earnings Per Share EPS Growth | 0.04 | 0.02 | -0.07 | -0.01 | -0.01 | -0.01 |
EPS Growth | 73.40% | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Wholesale - PCC/USA Wholesale - PCC/USA Growth | 0.44 | 0.7 | 0.89 | 0.04 | - |
Plant Based - UK/EU/JPN/AUS Plant Based - UK/EU/JPN/AUS Growth | 3.19 | 3.05 | 5.44 | 5.11 | 0.46 |
Manufacture/sales - Australia Manufacture/sales - Australia Growth | 44.14 | 24.68 | 3 | - | - |
Unallocated Unallocated Growth | - | 0.87 | 0.33 | 0.18 | 0 |
Total Total Growth | 48.05 | 29.3 | 9.66 | 5.34 | 0.47 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Investments Cash & Investments Growth | 7.6 | 7.67 | 1.03 | 3.85 | 0.07 | 1.6 |
Total Debt Total Debt Growth | 5.37 | 1.53 | 0.71 | 0.56 | 0.4 | - |
Net Cash (Debt) Net Cash Growth | 2.24 | 6.13 | 0.32 | 3.29 | -0.33 | 1.6 |
Net Cash Growth | -63.55% | 1831.58% | -90.34% | - | - | -5.78% |
Net Cash Per Share Net Cash Per Share Growth | 0.01 | 0.03 | 0.00 | 0.02 | -0.00 | 0.03 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 2.02 | 6.28 | -3.56 | -1.13 | -0.51 | 0.05 |
Capital Expenditures CapEx Growth | -1.74 | -2.07 | -0.18 | -0.06 | -0.06 | - |
Free Cash Flow Free Cash Flow Growth | 0.28 | 4.21 | -3.74 | -1.19 | -0.57 | 0.05 |
Free Cash Flow Growth | -93.27% | - | - | - | - | 264.26% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Gross Margin | 41.05% | 38.17% | 38.53% | 29.55% | 29.10% | 43.13% |
Operating Margin | 20.66% | 17.41% | -11.75% | -34.32% | -97.72% | -16.97% |
Pretax Margin | 18.65% | 16.74% | -134.56% | -36.16% | -106.55% | -22.49% |
Profit Margin | 18.70% | 16.74% | -138.19% | -36.61% | -106.55% | -22.49% |
FCF Margin | 0.59% | 14.37% | -38.77% | -22.45% | -122.27% | 2.41% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | 23.18 | 18.11 | - | - | - | - |
P/FCF Ratio | 746.74 | 21.09 | - | - | - | 337.34 |
PS Ratio | 4.41 | 3.03 | 1.06 | 7.18 | 16.57 | 8.13 |